DRESDEN, Germany--(BUSINESS WIRE)--Cenix BioScience GmbH (Dresden), the leading specialist in advanced RNA interference (RNAi)-based research services, today announced that it has signed a framework research agreement with AstraZeneca Pharmaceuticals LP, one of the world’s leading pharmaceutical companies, to advance the latter’s efforts in the discovery and validation of novel therapeutic drug targets.
